The results announced today, for the LNC version o
Post# of 63
Dr. Fauci also asked MTNB to use its LNC platform to try and make an oral version of Remdesivir that is safe and effective.
That study is also being funded by the NIH.
So, it appears the NIH is very supportive of MTNB, and its LNC platform, which makes FDA approval of various LNC formulations, including MAT 2202 and MAT 2501, highly probable in my opinion.
The Remdesivir results, along with the results of numerous collaborations with a who's who list of big pharmaceutical companies, could be announced at any time.
I have to believe that at some point one of MTNB's big pharma collaborators is going to make an offer to buy the company.
Whether that offer is made before the FDA approves one or more of MTNB's encochleated drugs, and whether the purchase includes Lypsido, are the only questions in my mind.
It would be imprudent, in my opinion, to sell any shares in MTNB at this time.